BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 20 2023
0mins
Source: businesswire
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Treatment Shows Significant Efficacy in Cancer Patients
- Significant Clinical Efficacy: The Bria-IMT treatment achieved complete resolution of right temporal lobe metastasis in a 66-year-old female patient, who survived 27 months post-enrollment, demonstrating the therapy's potential in heavily pre-treated patients.
- Evidence of Immune Activation: CD8 ImmunoPET imaging revealed a significant increase in CD8+ T cells in the cervical lymph nodes post-Bria-IMT treatment, indicating immune system activation that may contribute to long-term survival.
- Study Scale and Results: Among 54 heavily pre-treated metastatic breast cancer patients, 37 received the Bria-IMT regimen, with no reported treatment discontinuations related to Bria-IMT to date, indicating good safety and tolerability of the therapy.
- Future Research Prospects: The ongoing Phase 3 clinical trial (NCT06072612) by BriaCell will further validate the efficacy of Bria-IMT, potentially bringing new hope to cancer treatment.
Continue Reading
BriaCell's New Therapy Significantly Extends Survival in Breast Cancer Patients
- Impressive Survival Data: As of the latest assessment, nine patients treated with Bria-IMT since 2022 have survived over 18 months, significantly exceeding benchmarks for standard therapies, indicating the potential efficacy of this treatment.
- Strong Treatment Continuity: No Bria-IMT-related discontinuations have been reported to date, suggesting good tolerability of the regimen among patients, which may provide new treatment options for heavily pre-treated individuals.
- Clinical Trial Progress: The Bria-IMT regimen continues under Fast Track Designation from the US FDA, expected to offer more effective treatment options for late-stage breast cancer patients, addressing the urgent market need for new therapies.
- Future Research Directions: BriaCell's ongoing pivotal Phase 3 study will focus on overall survival as its primary endpoint, aiming to further validate the efficacy of Bria-IMT and promote its broader acceptance in clinical applications.
Continue Reading